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Abstract Coronary artery disease (CAD), also known as
ischemic heart disease (IHD), is the leading cause of
mortality in the western world, with developing countries
showing a similar trend. With the increased understanding
of the role of the immune system and inflammation in
coronary artery disease, it was shown that macrophages
play a major role in this disease. Costimulatory molecules
are important regulators of inflammation, and especially,
the CD40L-CD40 axis is of importance in the pathogenesis
of cardiovascular disease. Although it was shown that
CD40 can mediate macrophage function, its exact role in
macrophage biology has not gained much attention in
cardiovascular disease. Therefore, the goal of this review is
to give an overview on the role of macrophage-specific
CD40 in cardiovascular disease, with a focus on coronary
artery disease. We will discuss the function of CD40 on the
macrophage and its (proposed) role in the reduction of
atherosclerosis, the reduction of neointima formation, and
the stimulation of arteriogenesis.
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Introduction
The TNF receptor superfamily member 5 (TNFRSF5), or
CD40, is a costimulatory molecule that was originally
discovered on B-cells and other antigen presenting cells
(APCs) [110]. CD40 is activated by its ligand,
CD40L(TNFSF5) [89]. CD40 is expressed on a multitude
of immune cells and non-immune cells, with functions
varying per cell type [21, 41]. In B-cells, CD40 ligation
induces T-cell-dependent immunoglobulin class switching
[42], memory B-cell development [48], and germinal
center formation [71, 79]. In dendritic cells, CD40 ligation
induces more effective antigen presentation [17, 115, 124],
enhances T-cell stimulatory capacity, and induces pro-
duction of several inflammatory cytokines and chemokines
[18]. It was discovered recently that T-cells also express
CD40 but not much is known about its function. T-cell
CD40 seems to mediate CD8? T-cell memory [12], can
contribute to T-cell activation [107], and is associated with
autoimmune disease [142, 143]. On monocytes, CD40
stimulation induces the production of inflammatory
cytokines and chemokines [75], and matrix metallopro-
teinases [38] and, similar to CD40 on dendritic cells,
induces more potent antigen presentation [17, 115, 124].
The effects of CD40 on macrophages will be described in
detail below.
In the 1990s, it was discovered that blocking CD40L
limits atherosclerosis [91, 93, 128] and induces a
stable plaque phenotype in mice [90]. Thereafter, it was
shown that knocking out CD40, the receptor for CD40L,
& Esther Lutgens
e.lutgens@amc.uva.nl
1 Department of Molecular Cell Biology and Immunology, VU
University Medical Centre, Amsterdam, The Netherlands
2 Department of Medical Biochemistry, Academic Medical
Centre, Meibergdreef 15, 1105AZ Amsterdam, The
Netherlands
3 Department of Cardiology, VU University Medical Center,
Amsterdam, The Netherlands
4 Institute for Cardiovascular Prevention (IPEK), Ludwig
Maximilians University, Munich, Germany
123
Basic Res Cardiol (2016) 111:38
DOI 10.1007/s00395-016-0554-5
induced a similar phenotype [92]. Our laboratories have
shown the importance of CD40 on hematopoietic cells, and
macrophages in particular. We showed that a deficiency of
hematopoietic CD40 decreased atherosclerosis and induced
plaque stabilization in CD40 knock-out mice [92]. Mac-
rophages of these mice were of the regulatory M2 pheno-
type. We also showed that the antiarteriogenic protein
galectin-2 shifts proarteriogenic, CD40-negative macro-
phages into proinflammatory, and CD40-positive macro-
phages, resulting in compromised arteriogenesis [158]. We
identified galectin-2 to be highly expressed in monocytes
of human chronic total coronary occlusion (CTO) patients
with a poor collateral network, compared with CTO
patients with a well-developed collateral network [145].
These findings, in combination with the large overlap
between functions of CD40 and macrophages in cardio-
vascular disease, suggest an important role of macrophage-
specific CD40 in cardiovascular disease. Specific inhibition
of macrophage CD40 might act as a ‘‘double-edged sword’’
by inhibiting atherosclerosis and stimulating arteriogenesis,
resulting in a reduced ischemic burden without interfering
in adaptive immunity.
Macrophages in cardiovascular disease
Monocytes and macrophages largely contribute to the
pathophysiology of cardiovascular diseases, for example,
in atherosclerosis [4, 37, 57, 62, 120, 164] and arterio-
genesis [55, 58]. Both monocytes and macrophages can, at
the extremes, be divided in a proinflammatory phenotype
and a healing phenotype. The interplay and balance
between these two phenotypes have shown to be of
importance in, for example, atherosclerosis [25, 29, 130]
and myocardial infarction [37, 154]. In murine monocytes,
the proinflammatory phenotype is defined as Ly6C high,
while the healing phenotype is defined as Ly6C low [159].
Ly6C high monocytosis is regarded as one of the first steps
in the inflammatory response in atherosclerosis, as Ly6C
high monocytes activate endothelium, infiltrate into the
intima, and become lesional macrophages. Furthermore, in
atherosclerosis models, such as the apolipoprotein (ApoE)
deficient mouse, hypercholesterolemia is associated with
Ly6C high monocytosis. Inhibition of the Ly6C high
monocytosis abolishes atherosclerosis in hypercholes-
terolemic mice [26, 87, 136]. In humans proinflammatory,
or classical, monocytes are generally defined as CD14??/
CD16-, while the healing, or non-classical, phenotype is
defined as CD14?/CD16?? [166]. An intermediate,
CD14??/CD16? population can also be observed in
humans [99, 153]. In concurrence with the animal model
described above, in humans, CD14??/CD16- monocy-
tosis is associated with atherosclerosis and is an
independent predictor of cardiovascular events [61, 123].
In macrophages, the phenotypic spectrum is defined by the
proinflammatory M1 macrophages that are induced by
T-helper 1 cytokines, and by M2 macrophages that are
induced by Th-2 cytokines. The M2 macrophages can be
subclassified into wound healing (M2a), regulatory (M2b,
M2c), and M2d subtypes [24, 25, 104]. In addition,
atherosclerosis-associated macrophage phenotypes have
been discovered, i.e., M(Hb), Mox, Mhem, and M4 mac-
rophages [24, 25]. Consequently, a large number of mac-
rophage phenotypic markers have evokes (reviewed by
Mosser et al. [104]. and Colin et al. [25]). While CD40 is
not mentioned in these reviews, it has proved to be a dis-
tinctive marker for M1 macrophages [148, 149]. In
experimental atherosclerosis models, the M1 and the pla-
que specific M4 subtypes are proinflammatory and
proatherogenic and seem to cause a vulnerable plaque
phenotype. The M2 phenotype and the plaque specific
M(hb) and Mhem are anti-inflammatory and antiathero-
genic. The role of the Mox phenotype is currently not well
understood [25, 29]. The role of the M2 subtypes has not
been defined further yet. In arteriogenesis in animal mod-
els, the shift toward M2 phenotype (no data on subtypes)
improves arteriogenesis and reduces ischemia [51, 138,
140]. In humans, M1 macrophages are associated with
plaque instability, both in ischemic stroke and in myocar-
dial infarction [23, 81, 134]. A word of caution should be
added, regarding the dichotomous distinction between M1
and M2 macrophages, as these terms are increasingly dis-
couraged by immunologists. In vivo, a wide range of M1-
and M2-like macrophages can be distinguished. While
older studies use the M1/M2 nomenclature, it is now
encouraged to use multiple markers to describe the mac-
rophage phenotype [47]. However, this review will still use
the M1/M2 nomenclature, as the studies described all use
this nomenclature.
CD40 in clinical disease
Cardiovascular diseases share many traits of their patho-
physiology with other autoimmune diseases, such as
rheumatoid arthritis [68], systemic sclerosis [16], systemic
lupus erythematosus [3], or inflammatory bowel disease
[49, 72, 139]. CD40 and CD40L were shown to have a
pivotal role in these diseases [27, 33, 96, 114]. Interest-
ingly, higher sCD40L levels in patients with Crohn’s dis-
ease even predicted thicker intima and media in their
carotid arteries [72]. In cardiovascular diseases, blocking
CD40 signaling has never been tested in clinical trials.
Anta- and agonistic CD40 antibodies, however, have been
tested in other chronic inflammatory diseases and cancer.
Below is a brief overview of these trials and the
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effectiveness and side effects of blocking or activating
CD40 signaling.
In 1999, the first clinical trials started using an anti-
CD40L antibody as a treatment for systemic lupus ery-
thematosus, lupus glomerulonephritis, and immune
thrombocytopenic purpura. The anti-CD40L antibody
treatment showed an improvement in the number of pla-
telets in immune thrombocytopenic purpura but did not
improve performance scores in systemic lupus erythe-
matosus [11, 28, 69, 78]. Blocking CD40L was effective in
lupus glomerulonephritis, where it markedly reduced
hematuria. However, this trial was ended prematurely
because of the high incidence of thromboembolic events
[11]. These thromboembolic events are most likely due to
the fact that CD40L is also present on platelets, as inhi-
bition of CD40L causes platelet aggregates to become
unstable and to embolize [5]. Since the anti-CD40L anti-
body treatment was deemed unsafe, attention was shifted
toward the CD40 molecule.
Dacetuzumab is a humanized anti-CD40 agonistic mAb,
which triggers CD40-mediated signaling in various cell
types [53]. It has been tested in several hematologic
malignancies. In a phase I single agent study of patients
with relapsed B-cell non-Hodgkin’s lymphoma, six of 50
patients had objective response, and an additional thirteen
had documented stable disease [2]. For relapsed chronic
lymphocytic leukemia, a phase I single agent study was
performed. In this study, none of the patients achieved an
objective response; however, five out of twelve patients
showed stable disease [43]. In refectory multiple myeloma,
single agent therapy with dacetuzumab showed no objec-
tive response in a phase I study [60]. In refractory diffuse
large B-cell lymphoma, a phase I study initially showed
promising results of dacetuzumab as a single agent, with
objective responses in four of 46 patients and 13 cases of
stable disease [30]. However, a follow-up study showed no
benefit of dacetuzumab on top of the existing last-resort
chemotherapy [36]. In these studies, about two-thirds of
patient’s experienced adverse events classified as grade
1–2 out of 4 among them were fatigue, headache, pyrexia,
chills, nausea, anemia, thrombocytopenia, and hypoten-
sion. Non-infectious eye disorders, including conjunctivitis
and ocular hyperemia, were also seen. A few grade 3
adverse events were seen, including malignant neoplasm
progression, severe anemia, pleural effusion, thrombocy-
topenia, and severe infections. Some grade 4 events were
seen, including aseptic meningitis and hyperviscosity
syndrome [2, 30, 36, 43, 60].
Lucatumumab (or HCD122) is a fully humanized
antagonistic antibody against CD40 and exerts its primary
function through opsonization followed by antibody-de-
pendent cell-mediated cytotoxicity (ADCC) [53]. It has
been tested in a single-agent phase I study of relapsed
chronic lymphocytic leukemia [15]. Here, one of 26
patients had a partial response and sixteen had a
stable disease. For relapsed or refractory multiple mye-
loma, a single agent phase I study was performed in 28
patients. Twelve patients had a stable disease after treat-
ment and one patient maintained a partial response for up
to 8 months [8]. A phase I/IIa study was performed for
advanced non-Hodgkin and Hodgkin lymphoma in 111
patients. In this study, the overall response rate by com-
puted tomography among patients was 33 % [35]. Overall,
most adverse events observed in these studies were mild to
moderate, including neutropenia, thrombocytopenia, fati-
gue, headache, chills, fever, and nausea, cytokine release
syndrome symptoms (mostly grades 1–2, sometimes grades
3–4), non-infectious ocular inflammation, and elevated
hepatic enzymes. A few serious adverse events were seen,
including dyspnea, pyrexia elevated liver enzymes and
infections. One death due to severe sepsis was reported [8,
15, 35].
An antagonistic anti-CD40 antibody, ch5D12, has been
tested in 18 patients with mild to moderate Crohn’s dis-
ease. Based on Crohn’s Disease Activity Index (CDAI)
scores, the overall response rate was 70 %, remission was
achieved in 22 % of patients, and ch5D12 was well toler-
ated. Described side effects were mild, including headache,
muscle aches, or joint pains [70].
While the side effects are described as overall mild to
modest in these papers, this is in comparison with the
conventional therapy for cancer or Crohn’s disease. How-
ever, in chronic use for ischemic heart diseases, the side
effects would be more damaging than beneficial. Since
blocking CD40 or CD40L systemically is not suitable for
the treatment of ischemic heart diseases because of pre-
dicted severe side effects, such as immune suppression,
targeting CD40(L) downstream targets and selected CD40
effector cells may be a preferred strategy.
CD40 and macrophages
The findings described above, in combination with the
large overlap between functions of CD40 and macrophages
in cardiovascular disease suggest an important role of
macrophage-specific CD40 in cardiovascular disease.
Unfortunately, there is not much data available on signal-
ing pathways elicited by CD40 in macrophages or macro-
phage subtypes. Since CD40 is expressed mostly on M1
macrophages [148, 149], it can be assumed that CD40
signaling is predominantly active in M1 macrophages.
Ligation of CD40 on macrophages induces a more potent
antigen presentation, with the upregulation of MHC class
II, costimulatory molecules CD80, CD86, and CD40 itself
[135]. Furthermore, ligation of CD40 stimulates the
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production of proinflammatory cytokines and chemokines
by macrophages, including TNFa, IL-1 (a and b), IL-6, IL-
8, IL-12, CCL 2, 3, 4, and 5 [135]. CD40 also induces
several other molecules, such as matrix metalloproteinases,
nitric oxide, and possibly iNOS (NOS2) and COX-2. In
addition, ligation of CD40 on near-apoptotic cells rescues
them from apoptosis [118, 135].
However, since these studies are all performed in vitro,
caution is needed when interpreting these interactions as the
response CD40 induces in macrophages seems highly
dependent on the environment. In vitro, the presence of IL-4
or IL-10 has been shown to induce quite different results in
downstream CD40 signaling in macrophages. IL-4 blocks
CD40 mediated rescue from apoptosis, while IL-10 does not
[117]. IL-10 significantly inhibitedCD40-induced activation
of the ERK, p38MAPK, andNF-jB pathways, whereas IL-4
only affects the ERK pathway [66]. CD40-CD40L interac-
tion induces ROS production, the synthesis of ICAM1, and
activation of stress response proteins (p38 MAP kinase and
HSP27) only in the presence of hypoxia, indicating that
CD40(L) mediates the induction of oxidative stress in these
cells [20]. When comparing a model of an atherosclerotic
plaque in mice [90] to a model of lung fibrosis in mice [1],
opposite reactions to the same stimuli are seen due to the
influence of tissue environment on CD40 signaling. In both
models, inhibition of CD40-CD40L signaling results in a
downregulation of inflammation. However, in atheroscle-
rosis, anti-CD40L antibody treatment resulted in the upreg-
ulation of TGF-beta onmacrophages, whereas in irradiation-
induced lung injury, it caused downregulation of TGF-beta.
Environmental differences like these are important in
tumor progression [111, 113], but there is also indirect
evidence that these environmental differences play a role in
other diseases. For example, the lack of apoptosis of
macrophages inside the atheromatous plaque is thought to
aggravate atherosclerosis [88, 146]. It was shown that IL-4
blocked CD40-mediated rescue from apoptosis, while IL-
10 does not [117]. Though never proven, one could
imagine that the plaque environment alters CD40 signaling,
and thus affects atherosclerosis.
TNF-receptor-associated factors
As CD40 does not have the ability to initiate its own
intrinsic activity but requires adaptor molecules, it is
important to note the functions of these molecules, with a
focus on their functions in macrophages. The TNF-recep-
tor-associated factor (TRAF)-family of proteins can bind to
the cytoplasmic tail of CD40 and subsequently recruit
kinases and other effector proteins [127]. All TRAF-family
members, with the exception of TRAF5, are ubiquitously
expressed, suggesting that they may perform significant
physiological and cellular functions in multiple organs and
cell types. The TRAF-family members can be recruited by
a variety of receptors, among which CD40. CD40 can, after
activation by CD40L, recruit several different TRAF-
family members. Depending on the TRAF-molecule acti-
vated, different transduction cascades are induced. These
transduction cascades activated by the different TRAFs can
have opposite effects. Unfortunately, what regulates the
recruitment of a certain TRAF-family member to CD40
remains unclear. Of the seven known TRAF-family mem-
bers, CD40 can bind five (TRAFs 1, 2, 3, 5, and 6) [119,
155]. CD40 contains three binding sites, one for the TRAF
1, 2, and 3, one for TRAF6 [119] and a secondary TRAF2
binding site. There is some conflicting evidence whether or
not TRAF 5 can bind directly to the binding site of TRAF
1, 2, and 3 [67] or that it indirectly binds to it via an
heterodimeric complex with TRAF3 [119, 161]. Below is a
brief description of the different functions of the TRAF
proteins when CD40 ligation occurs. A graphical overview
of the main pathways involved in CD40-TRAF signaling is
shown in Fig. 1. As TRAF4 and TRAF7 do not bind to
CD40, they will not be discussed.
TRAF1
TRAF1, like all TRAFs, can be recruited to a variety of
TNRF receptor members, including CD40, TNFR I/II, and
RANK [64]. In general, it is thought that TRAF1 has a role as
a negative regulator of signaling in TNF receptors. This is
displayed in TRAF1 knock-out models, where T-cells
respond in a hyper proliferative manner in response to
stimulation [82, 162]. However, the possible role as negative
regulator has not yet been researched inmacrophages. On the
CD40 protein, TRAF1 shares a binding site with TRAF 2 and
3 and binds only weakly to this site [119]. No functional data
are known about CD40-TRAF1 signaling on macrophages.
However, ligation of CD40 on T- and B-cells that were
deficient in TRAF1 did not show any differences compared
with normal T- and B-cells [82, 162]. However, in cell cul-
tures of dendritic orHeLAcells, TRAF1 negatively regulates
CD40-TRAF2 signaling [6, 40]. Of interest, this review is a
study by Missiou et al., which showed that TRAF1 defi-
ciency reduces atherosclerosis by limiting the adhesion of
monocytes to the vessel wall, suggesting that TRAF1 plays a
role in monocyte adhesion [97]. However, since TRAF1
interacts with more receptors that just CD40, it is not known
if this inhibition of adhesion was solely due to the lack of
CD40-TRAF1 signaling.
TRAF2
The general functions of TRAF2 are very broad. TRAF2 is
required in T- and B-cell signaling and inflammatory
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responses, but it is also required for organogenesis and cell
survival [7]. TRAF2 activates the canonical NF-jB sig-
naling pathways [103] and also seems to be a negative
regulator of the non-canonical NF-jB signaling pathways,
as TRAF2 deficiency results in hyperreactivity of this
pathway [7]. On the CD40 protein, TRAF2 shares its
binding site with TRAF1 and 3. It binds strongly and
directly to this binding site [119]. TRAF2 seems to require
an intact lipid raft to function, as CD40-TRAF2 signaling
on dendritic cells is largely absent when disturbing the lipid
raft [147]. On the macrophage, some evidence points
toward the requirement of TRAF2 expression and subse-
quent degradation after stimulation with CD40L for the
differentiation of monocytes into fully functional macro-
phages [34], suggesting that TRAF2 has a low concentra-
tion in macrophages. A defective TRAF2, 3, and 5 binding
site on CD40 in macrophages does not completely impair
the inflammatory response to CD40L; however, it does
result in a lower TNF production (ca. 40 % of total pro-
duction). Furthermore, CD40-TRAF2/3/5 deficiency leads
to an inability to activate the IKK complex. However, this
defect has no consequences for NF-kB activation, IL-6
production, or ERK1/2 activation [65, 106].
TRAF3
The function of TRAF3 has long been a mystery, as
researching it proved difficult. TRAF3 knockout mice have
a relatively normal gestation period; however, soon after
birth, the mice die prematurely within two weeks of age
with symptoms, including stunted growth and progressive
hypoglycemia, hypercortisolemia, and leukopenia [54].
Relatively, recently, it was discovered that TRAF3 is a
powerful negative regulator of the non-canonical NF-jB
signaling pathways and a modulator of viral immunity [54].
On the CD40 molecule, as mentioned before, TRAF3
Fig. 1 Overview of the main
pathways involved in CD40-
TRAF signaling. a TRAF 2/3/5
induces about 40 % of TNF
production; however, they do
not influence (canonical) NF-
jB. Therefore, an alternative
pathway must be present. Based
on data from B-cells, this is
most likely the non-canonical
NF-jB pathway. b TRAF 2/3/5
is required for the IKK-
complex; however, they do not
influence (canonical) NF-jB.
Therefore, an alternative
pathway is likely present.
c Much of the downstream
targets of CD40-TRAF
signaling still need to be
uncovered. Of the majority of
molecules produces by
macrophages in response to
CD40 signaling, no TRAF
molecule or further pathway has
been determined
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shares its binding site with TRAF1 and 2. It binds strongly
and directly to this binding site [119]. TRAF3, like TRAF2,
also seems to require an intact lipid raft to function;
however, the effect of disturbing the lipid raft is not as
large as with TRAF2 [147]. On macrophages, TRAF3 is
suggested to only be present in low concentrations.
Monocytes showed a strongly immunoreactivity for
TRAF3, but macrophages typically contained little or no
TRAF3 immunoreactivity [77].
TRAF5
TRAF5 is highly similar to TRAF2, in both structure and
function. However, whereas TRAF2 is expressed ubiqui-
tously, TRAF5 expression is only found at significant
levels in lung, thymus, spleen, and kidney and at lower
levels in the brain and liver [7]. A sole TRAF5 deficiency
has interesting consequences. TRAF5 deficiency acceler-
ates atherogenesis in a mice model by promoting the roll-
ing and adhesion of inflammatory cells and macrophage
LDL uptake, which might contribute to foam cell forma-
tion [98], suggesting an anti-inflammatory, antiatherogenic
function of TRAF5. It is under discussion whether TRAF5
directly [67] or indirectly binds to CD40 via hetero-oli-
gomers with TRAF3 [119, 161].
TRAF6
Generation of TRAF6 deficient mice revealed that TRAF6
plays crucial roles in several important processes and that
other TRAFs cannot compensate for loss of TRAF6. These
functions are extremely broad, including osteoclastogene-
sis, lymph node organogenesis, thymic selection, and
central tolerance. It is essential for IL-1 signaling and
required for most TLR-receptor signaling [63, 151]. Fur-
thermore, TRAF6 mediates antiviral responses triggered by
cytosolic viral DNA and RNA in a way that differs from
that associated with TLR signaling [76]. On the CD40
protein, TRAF6 has a separate binding site, to which it
weakly binds [119]. Upon binding, TRAF6 is required for
the maturation of dendritic cells, the affinity maturation of
immunoglobulins, and optimal function of CD8? T-cell
homeostasis and memory development [63, 151]. In
monocytes and macrophages, TRAF6 is responsible for the
most downstream actions of CD40. It is required for TNF
production, IL6 production, NF-jB activation (through p62
[129]), ERK activity, IKK activation, PKR phosphoryla-
tion [106], and upregulation of NOS2 (in cooperation with
TNF) [118]. Defective CD40-TRAF6 signaling has some
interesting results in monocytes and macrophages. This
deficiency induces the polarization of macrophages toward
an anti-inflammatory regulatory M2 signature, induces a
reduced blood count of Ly6C high monocytes, and results
in impaired recruitment of Ly6C high monocytes to the
arterial wall. This defective signaling also results in a
marked reduction of atherosclerosis in a mouse model [22,
92]. Recently, a small molecule CD40-TRAF6 inhibitor
was developed. This compound showed significant survival
benefits in sepsis and peritonitis in mice, with little side
effects [163]. Furthermore, in a diet-induced obesity
model, it was shown that the small molecule inhibitor
reduced insulin resistance and, most important for this
review, reduced the accumulation of immune cells to the
adipose tissue and by skewing of the immune response
toward a more anti-inflammatory profile [22, 144].
Atherosclerosis
In the pathophysiology of coronary artery disease, macro-
phage-specific CD40 plays a role in four major processes
of the disease, atherosclerosis, neointima formation,
angiogenesis, and arteriogenesis. Below the role of CD40
and macrophage-specific CD40 in these four processes will
be described.
In atherosclerosis, atheromatous plaques develop due to
the accumulation of apolipoprotein B containing lipopro-
teins in the inner lining of large- and medium-sized arteries
[101]. When the coronary vasculature is affected, this can
lead to ischemic heart disease. Ischemic heart disease is an
important determinant of morbidity and mortality in
developed countries, and is soon to attain this status
worldwide [105]. As the atheromatous plaques develop,
they grow larger and can restrict the vessel lumen resulting
in symptoms, such as angina pectoris or claudicato inter-
mittens, depending on the arterial bed affected. When
atherosclerosis progresses, there is an increase in the
incidence of the acute and most damaging complications,
such as myocardial infarctions or ischemic cerebrovascular
events. These acute complications of atherosclerosis are
caused through either the rupture of a vulnerable plaque or
the erosion of the endothelial layer [85, 108].
In the 1990s, it was discovered that inhibition of CD40
signaling by blocking CD40L limits the evolution of
established atherosclerosis in mice [91, 93, 128]. In con-
currence with these findings, it was shown that both early
and delayed anti-CD40L antibody treatment induced a
stable plaque phenotype [90]. Furthermore, it was shown
that platelet CD40L mediates thrombotic and inflammatory
processes in atherosclerosis [86]. Moreover, Leroyer et al.
showed that microparticles isolated from human
atherosclerotic lesions express CD40L, stimulate endothe-
lial cell proliferation after CD4 ligation, and promote
in vivo angiogenesis. The majority of these microparticles
(93 %) were of macrophage origin, and therefore,
microparticles released by macrophages could represent a
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major determinant of intraplaque neovascularization and,
thus, plaque vulnerability [83]. In humans, CD40L predicts
cardiovascular events. In unstable coronary artery disease,
expression of CD40L on platelets and serum soluble
CD40L levels are higher in patients compared with
stable coronary disease or peripheral arterial disease [10,
45]. Furthermore, some studies show that sCD40L con-
centrations can predict clinical outcome in patients with
acute coronary syndrome. However, other studies report no
correlation between sCD40L levels and clinical outcome
[112]. CD40L antibodies were tested clinically for other
autoimmune diseases (see ‘‘CD40 in clinical disease’’).
However, trials were ended because of the high incidence
of thromboembolic events [11]. These were most likely
caused by to the fact that CD40L is also present on pla-
telets, and inhibition of CD40L causes platelet aggregates
to become unstable [5].
Thus, attention was shifted toward the CD40 protein.
The involvement of CD40 signaling in atherosclerosis has
been firmly established. In a mouse model that lacked both
ApoE and CD40-TRAF6 signaling, atherosclerosis was
abolished. Furthermore, the defective CD40 signaling
induced a clinically favorable plaque phenotype, contain-
ing a high amount of fibrosis and a few inflammatory cells
[92]. Furthermore, it was also shown that macrophage foam
cell formation is highly dependent on CD40 in a study by
Yuan et al. Soluble sCD40L significantly increased lipid
deposition and foam cell formation. Disruption of the
ligation between CD40 and CD40L either by small inter-
fering RNA or by a blocking anti-CD40 antibody inhibited
foam cell formation in response to sCD40L [160].More-
over, a meta-analysis of the rs1883832 CD40 SNP has
shown a correlation between the C allele of this SNP and
acute coronary syndrome in a Chinese population [157].
There is convincing evidence, suggesting a large role of
CD40 on macrophages in atherosclerosis. The mouse
knock-out model described above that lacked both ApoE
and CD40-TRAF6 signaling displayed a reduced blood
count of Ly6C high monocytes, an impaired recruitment of
Ly6C high monocytes to the arterial wall, and polarization
of macrophages toward an anti-inflammatory regulatory
M2 signature. The reduction in atherosclerosis and the
macrophage phenotype shift, both induced by defective
CD40-TRAF6 signaling, is suggestive for a large role of
CD40 on macrophages in atherosclerosis. In patients,
CD40 on monocytes and macrophages is a marker for
atherosclerosis, as shown by Bruemmer et al., who dis-
covered that there is a direct association of CD40 expres-
sion on macrophages and smooth muscle cells and intimal
thickness, suggesting a role in early plaque development
[13]. In addition, CD40 on macrophages is associated with
critical limb ischemia [14] and coronary artery calcification
[137] in patients. Furthermore, patients with moderate
hypercholesterolemia showed a significant increase in
CD40 on monocytes (together with CD154 and P-selectin
on platelets) compared with healthy subjects. A short-term
therapy with an HMG-CoA reductase inhibitor signifi-
cantly downregulated CD40 on monocytes [46, 150].
Unfortunately, a model detailing the effect on atheroscle-
rosis by a specific deletion of CD40 on macrophages has
not been published yet. On a side note, the difference
described between males and females in the prevalence in
cardiovascular diseases [141] might be in part due to a
difference in CD40 on human macrophages. Androgens
increase the expression of CD40 (among other
atherosclerosis related genes) in male but not female
macrophages, with functional consequences [109].
Neointima formation
Essentially, all damage to the vascular wall results in an
increase in intimal thickness, or neointima formation. This
process is associated with luminal narrowing, causing
major complications in humans after arterial intervention
(e.g., balloon angioplasty and stenting). In neointima for-
mation, vascular smooth muscle cells proliferate within the
intima. This process has been the main target for treatment
in the form of drug eluting stents. However, the immuno-
logical process driving smooth muscle cell proliferation
has not been fully uncovered, though initial cytokine
release from platelets and macrophages, and further
aggravation through macrophage produced cytokines has
been suggested [19, 74]. A role for CD8? T-cells has also
been shown, where the absence of CD8? cells increases
neointima formation. Conversely, the absence of CD4?
T-cells reduces neointima formation [31, 165].
In ApoE deficient mice in which denudation injury to
the carotid arteries was induced, it was shown that blocking
CD40L significantly reduced the exaggerated neointima
formation, with a[50 % reduction in neointimal size and a
56 % reduction in neointimal macrophage content [84].
Moreover, it was shown that blocking CD40L-CD40 sig-
naling but not CD40L-Mac-1 reduces neointima formation
[152]. In other studies, it was shown that neointima for-
mation after both carotid artery ligation and femoral artery
denudation injury was reduced in CD40-deficient mice
compared with wild-type mice. Furthermore, a significant
decrease in the recruitment of neutrophils (at 3 and 7 days)
and macrophages (at 7 and 21 days) into injured artery was
shown [59, 132]. Some contradictory data exist as Remskar
et al. showed that after carotid artery injury in CD40L
knockout mice, the intimal thickening was increased 3-fold
compared with the thickening in wild-type mice [122].
Furthermore, it was shown by Donners et al. that inhibition
of CD40L signaling did not reduce neointima formation in
Basic Res Cardiol (2016) 111:38 Page 7 of 16 38
123
mice. CD40-knock-out mice, however, did have reduced
neointima formation in the same study, suggesting that
CD40, but perhaps not CD40L, plays a large role in
neointima formation [32].
Like in atherosclerosis, TRAF6 seems to be the key
regulator of CD40 signaling in neointima formation and
arterial remodeling. Donners et al. showed that in mice
deficient for CD40-TRAF6 signaling, neointima volume
was reduced by 83 %. Also like atherosclerosis, they
showed an impaired recruitment of macrophages to the
vessel wall [32]. Another study demonstrated that in rabbits
where carotid artery damage was induced by balloon
inflation, CD40-TRAF6 signaling deficiency inhibited
intimal cell replication, macrophage infiltration, and pro-
teoglycan accumulation [100]. The role of CD40-TRAF6
signaling on vascular wall cells was also shown to be of
importance, cooperating with kinase TAK1 [131, 133].
These data suggest a possible strategy for preventing
neointima formation and, thus, improve outcome after
vascular intervention by interfering in the CD40, most
likely CD40-TRAF6, signaling of macrophages. However,
no indication of its effectiveness compared with drug
eluting stents, the current clinical practice, has been made.
Angiogenesis
Angiogenesis, a process seen in both health and disease,
refers to the formation of new capillaries. The process of
angiogenesis starts when several proangiogenic factors,
such as vascular endothelial growth factor (VEGF) or basic
fibroblast growth factor (bFGF), are excreted as a reaction
to ischemia. These factors act by activating endothelial
cells, causing them to proliferate and migrate into the
perivascular space and eventually resulting in the forma-
tion of a new capillary lumen.
While angiogenesis is required for wound healing,
increased angiogenesis is also associated with increased
tumor growth and tumor metastasis [39, 80, 116]. This
duality can also be in cardiovascular disease. Here,
angiogenesis relieves ischemia by sprouting new capillar-
ies [156] but also aggravates atherosclerosis by increasing
plaque vascularization [102]. The functions of bFGF and
VEGF are well known and often studied; however, other
molecules, like CD40, seem to play crucial roles as well.
As described above, VEGF is a potent initiator of
angiogenesis. Several studies have described a regulatory
role for monocyte or macrophage CD40 in VEGF pro-
duction. A study by Melter et al. shows that the treatment
of HUVECs and monocytes with soluble CD40 ligand
(sCD40L) results in an induction of VEGF and VEGF-
mRNA. In an in vitro endothelial cell growth assay,
CD40L induced marked growth of HUVECs. Neutralizing
anti-VEGF antibody completely inhibited the effect of
sCD40L on HUVEC growth. The study also showed a
model of SCID mice bearing human skin transplants.
sCD40L was injected into the human skin grafts and a
marked induction in VEGF expression was found after
7 days in all sCD40L-treated skins compared with controls
[95]. A similar study, performed for 6 weeks, showed
similar results. In a model of SCID mice bearing human
skin transplants, it was found that the injection of CD40L-
expressing cells, but not control cells, resulted in the
in vivo expression of several angiogenesis factors (in-
cluding VEGF and fibroblast growth factor) and a marked
angiogenesis reaction [121]. Yet, another study showed
that MCP-1 and CD40L stimulation of macrophages had a
synergistic effect on COX-2 expression and subsequent
VEGF production in gastric cancer [44]. All these studies
clearly suggest that CD40 ligation is a potent stimulator
angiogenesis and that the proangiogenic effect of CD40 is
VEGF dependent.
While not many studies describing angiogenesis and
CD40 on macrophages have been done, from the few that
have been done a clear picture emerges, macrophage CD40
ligation induces and controls VEGF and other angiogenic
factors, and seems to be an important factor in
angiogenesis.
Arteriogenesis
Arteriogenesis refers to the widening of existing collateral
arteries, as to increase blood flow.
These existing collateral arteries are present at birth and
can be considered as alternative ways blood can flow from
one point to another. Thus, when a vessel becomes partially
obstructed, collateral vessels are somewhat able to com-
pensate for the loss of blood flow. Arteriogenesis causes
these collateral vessels to widen as to increase to blood
flow to its original state.
The exact mechanisms of arteriogenesis have not yet
been unraveled. Arteriogenesis is initiated by an increase in
shear stress, caused by an increased blood flow in the
collateral artery after partial obstruction of the main artery.
The shear stress causes endothelial cells to become acti-
vated, and expresses several chemo-attractants and adhe-
sion molecules [56]. These cause monocytes to adhere,
migrate, and change into macrophages. These macrophages
start to produce several cytokines and growth factors,
which cause smooth muscle cells (SMCs) to proliferate,
facilitating vascular luminal expansion and, thereby, an
increased collateral perfusion.
It has been shown that having increased arteriogenesis,
and thus, a better collateral network is highly beneficial.
Patients with a better collateral network have smaller
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lesions after myocardial infarction, less ventricular aneur-
isms, a relatively better left ventricular ejection fraction
[50], less future cardiovascular events [9], and an improved
survival [52, 94].
High expression of several immune modulating proin-
flammatory agents, such as Interferon-beta and Galectin-2,
were shown to correlate with poor collateralization in
humans and to directly inhibit this process in murine
models [126, 145, 158]. It has been shown that the balance
between M1 and M2 macrophages is of importance in
arteriogenesis. For example, in a mouse model by Takeda
et al., skewing macrophages toward the M2-phenotype
resulted in an increase in arteriogenesis and a marked
decrease in ischemia as a result [23, 81, 134]. Although no
direct studies on CD40 and arteriogenesis have been done,
it has been convincingly shown that CD40 on macrophages
might be involved. In a mouse model to test the effects of
galectins on arteriogenesis, they show that galectin
administration leads to increased numbers of CD40-posi-
tive M1 macrophages and reduced numbers of M2
Fig. 2 Overview of the proposed mechanisms of CD40 (-TRAF6)
inhibition on ischemic heart diseases. a In neointima formation,
CD40(-TRAF6) inhibition reduces monocyte/macrophage recruit-
ment into the vessel wall and shifts the macrophage subset balance
toward the regulatory M2 phenotype. CD40(-TRAF6) inhibition
markedly reduces neointima formation. b In atherosclerosis, CD40(-
TRAF6) inhibition induces Ly6C low monocytosis in mice (the
human counterpart to Ly6C low is CD14?/CD16??). Furthermore,
it reduces monocyte/macrophage recruitment into the plaque, shifts
the macrophage subset balance toward the regulatory M2 phenotype
and reduces the formation of foam cells. CD40(-TRAF6) inhibition
abolishes atherosclerosis. c In arteriogenesis, CD40(-TRAF6) inhibi-
tion induces Ly6C low monocytosis in mice (the human counterpart
to Ly6C low is CD14?/CD16??). Moreover, shifts the macrophage
subset balance toward the regulatory M2 phenotype. Both these
changes have been shown to be highly beneficial in arteriogenesis
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macrophages surrounding actively remodeling collateral
arteries [158]. Suggesting that, in concurrence with the data
described above, the shift toward CD40 positive M1
macrophages slows down arteriogenesis. As described
above in the data presented about atherosclerosis, inter-
fering with CD40 macrophage signaling induces a pheno-
type shift from M1 to M2 macrophages. While not many
evidence exist yet, this might yield interesting new thera-
pies for ischemic diseases.
Discussion
Macrophages are one of the most versatile cells, and the
CD40 receptor on these cells has an equally large range of
functions. As described above, there is substantial evidence
for a large role of CD40 on macrophages in ischemic heart
disease. Evidence is presented that the activation of CD40
on macrophages accelerates atherosclerosis, accelerates
neointima formation, and attenuates arteriogenesis. The
downstream target of CD40, TRAF6, plays a major role in
these processes. An overview of the proposed mechanisms
of CD40 inhibition on ischemic heart diseases is shown in
Fig. 2.
While much research still needs to be done, the data
presented in this review suggest that interfering in CD40
signaling on the macrophage is an excellent candidate for
future cardiovascular therapies. Targeting CD40 specifi-
cally on the macrophage can be done in several ways.
Macrophage-specific CD40 can be inhibited using a bis-
pecific antibody that binds to both CD40 and a macrophage
specific receptor. However, a more practical way is to use
liposomes or HDL nanoparticles containing a CD40(-
TRAF6) inhibitor. These particles naturally target phago-
cytic cells, particularly macrophages, and thus specifically
deliver the drugs to these cells [73, 125]. Theoretically, a
patient’s ischemic burden could be drastically lowered by
reducing or inhibiting CD40 signaling on macrophages. It
could act as a ‘‘double-edged sword’’ by reducing the cause
of ischemic heart disease (atherosclerosis) and promoting
the cure (arteriogenesis). Equally important is the notion
that reducing or inhibiting CD40 signaling on macrophages
would not induce new problems, such as heightened tumor
growth (induced by increased angiogenesis) or immune-
suppression (by not interfering in the adaptive immune
system). Although significant research is still required,
CD40 on macrophages is an exciting and potent therapeutic
target. A drug targeting this interaction could possibly lead
to new therapies and improved care in cardiovascular
disease.
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